



(51) International Patent Classification:

C12N 15/38 (2006.01) *C07K 14/04* (2006.01)
A61K 39/25 (2006.01) *C12N 15/87* (2006.01)
A61P 31/22 (2006.01) *C12N 15/113* (2010.01)
A61P 37/04 (2006.01)

(21) International Application Number:

PCT/CA2024/050073

(22) International Filing Date:

23 January 2024 (23.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/073462

24 January 2023 (24.01.2023) CN

(71) Applicant: **PROVIDENCE THERAPEUTICS HOLDINGS INC.** [CA/CA]; 120-8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA).

(71) Applicant (for CN only): **EVEREST MEDICINES (CHINA) CO., LTD.** [CN/CN]; F2, #4 Building, Xinda Road, No. 8, Huimin Street, Jiashan County, Jiaxing, Zhejiang 314199 (CN).

(71) Applicant (for all designated States except CN): **EVEREST MEDICINES (SINGAPORE) PTE. LTD.** [SG/SG]; 30 Cecil Street, #19-08 Prudential Tower, Singapore 049712 (SG).


(72) Inventors: **MARTIN OROZCO**, Natalia; 120-8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **ARITA, Yuko**; 120-8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **LIU, Jun**; 120-8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **MARCUSSON, Eric G.**; 120-8832 Blackfoot Trail SE, Calgary, Alberta T2J 3J1 (CA). **CHI, Xiaoyuan Sherry**; F2, #4 Building, Xinda Road, No. 8, Huimin Street, Jiashan County, Jiaxing, Zhejiang 314199 (CN). **LIU, Xinan**; F2, #4 Building, Xinda Road, No. 8, Huimin Street, Jiashan County, Jiaxing, Zhejiang 314199 (CN). **FAN, Yue**; F2, #4 Building, Xinda Road, No. 8, Huimin Street, Jiashan County, Jiaxing, Zhejiang 314199 (CN). **YANG, Kejian**; F2, #4 Building, Xinda Road, No. 8, Huimin Street, Jiashan County, Jiaxing, Zhejiang 314199 (CN). **YANG, Wei Jennifer**; F2, #4 Building, Xinda Road, No. 8, Huimin Street, Jiashan County, Jiaxing, Zhejiang 314199 (CN).

(74) Agent: **ROBIC AGENCE PI S.E.C. / ROBIC IP AGENCY LP**; 630 Rene-Levesque Boulevard West, 20th Floor, Montreal, Quebec H3B 1S6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV)

Fig. 5B



(57) Abstract: The present disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of nucleic acid vaccines comprising polynucleotide sequences encoding one or more structural proteins of a varicella-zoster virus (VZV) for the treatment, mitigation, amelioration and/or prevention of shingles.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*